June 1, 2011
/PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications has announced a new five-year exclusive U.S. distribution agreement with Anika Therapeutics S.r.l., a wholly owned subsidiary of Anika Therapeutics, Inc. (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair. Misonix will sell and distribute Anika's Hyalomatrix® product, a skin substitute based on hyaluronic acid technology. Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds and will be a companion product for Misonix's SonicOne® Ultrasonic Wound Cleansing and Debridement System.
Anika will manufacture and supply finished product to Misonix, while Misonix will be responsible for all aspects of commercialization in
the United States
. A recognized leader in advanced ultrasonic wound management, Misonix has U.S. sales and marketing organizations for both the surgery and clinic settings, where acute and chronic wounds are treated. Both sales organizations will market the Hyalomatrix product offering.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to expand its presence in the rapidly growing advanced wound care market by undertaking the U.S. distribution of another state-of-the-art wound care product," said
Michael A. McManus, Jr.
, President and Chief Executive Officer of Misonix. "Anika's Hyalomatrix skin substitute will hold an important position in our treatment protocol for advanced wound management and is synergistic to our own SonicOne product line.
"This Agreement demonstrates the Company's continued commitment to growth in large markets either by organic growth or the distribution of synergistic world class products through our domestic sales forces. The addition of Hyalomatrix is consistent with our plan to leverage the value of our existing distribution organization by adding more high value products to our sales pipeline."